BACE1 and Alzheimer disease: Given Aβ deposition commencing decades before the symptom onset (Bateman et al., 2012) (Figure 1), symptomatic AD brains already harbor significant Aβ burden less sensitive to BACE1 inhibitor interventions (Peters et al., 2018) and even if reduced, downstream detrimental consequences of Aβ may continue.